Ultrapotent SARS coronavirus-neutralizing single-domain antibodies that bind a conserved membrane proximal epitope of the spike

Sieglinde De Cae, Inge Van Molle, Loes van Schie, Sophie R. Shoemaker, Julie Deckers, NincyDebeuf, Sahine Lameire, Wim…

Bio€quity Europe— May 12-14, 2023 – Dublin, Ireland

Excited to be a part of the Presenting Company Class of 2023 at BioEquity: Europe 2023!

ExeVir Bio and VIB Announce Data on a New Therapy for Prevention and Treatment for COVID-19 (EN/FR/NL)

ExeVir Bio and VIB-UGent’s bioRxiv pre-print reports on S2-binding camelid single-domain antibody-based drug, XVR013, that targets the Achilles’ heel in the SARS-CoV-2 viral spike

Focus on protecting the millions of immuno-compromised patients, who are most vulnerable to COVID-19

ExeVir Bio secures EUR 25 million venture debt financing from the European Investment Bank (EN/FR/NL)

Financing to advance the scientific development of innovative COVID-19 nanobody treatments focused on protecting high-risk immunocompromised individuals

Company developing highly potent antibodies targeting the conserved S1 and S2 regions of SARS-CoV-2

Bio Partnering at JPM — January 9-12, 2023 – San Francisco, CA

ExeVir is a clinical-stage company developing novel antibody therapies that help patients ward off infectious diseases. Our focus is on protecting populations unable to benefit from vaccines, such as immunocompromised individuals. The versatile VHH platform enables both prevention and treatment of bacterial and viral threats.